Biological therapies and Respiratory Syncytial Virus. Nirsevimab approval and the currently available alternatives in Mexico

2023, Number 5

Acta Pediatr Mex 2023; 44 (5)

Aguilar IF

Language: Spanish
References: 3
Page: 415-416
PDF size: 141.83 Kb.

Text Extraction

No abstract.

REFERENCES

https://www.fda.gov/news-events/press-announcements/la-fda-aprueba-un-nuevo-medicamento-para-prevenir-elvirus-respiratorio-sincitial-en-bebes-y-ninos
https://www.cdc.gov/rsv/clinical/index.html
https://www.aap.org/en/pages/2019-novel-coronaviruscovid-19-infections/clinical-guidance/interim-guidancefor-use-of-palivizumab-prophylaxis-to-prevent-hospitalization/